• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症改变了骨保护素与慢性肾脏病患者死亡率的关系。

Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.

机构信息

Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.

出版信息

J Nephrol. 2009 Nov-Dec;22(6):774-82.

PMID:19967657
Abstract

BACKGROUND

The production and expression of osteoprotegerin (OPG), a bone regulating protein, is regulated by inflammatory cytokines.

METHODS

As clinical and experimental studies have implicated OPG in atherogenesis, we investigated serum OPG in relation to inflammation, endothelial dysfunction and oxidative stress markers in 265 chronic kidney disease (CKD) stage 5 patients. Cardiovascular disease (CVD), carotid plaques (n=69) and mortality (5 years) in relation to OPG were also analyzed, and the impact of inflammation on the association of OPG with mortality was evaluated.

RESULTS

OPG correlated positively with circulating surrogate markers of inflammatory, endothelial dysfunction and oxidative stress. Patients with clinical CVD or carotid plaques had higher concentrations of OPG than their respective counterparts. Increased OPG levels per se were related to higher cardiovascular and all-cause mortality even after adjustment for age, sex, C-reactive protein, diabetes mellitus and baseline CVD. Moreover, the presence of inflammation further and independently aggravated the hazard ratios (HR) for both cardiovascular (HR=2.8; 95% confidence interval [95% CI], 1.3-6.4; p=0.01) and all-cause (HR=2.5; 95% CI, 1.4-4.5; p<0.01) mortality.

CONCLUSIONS

Elevated OPG levels are associated with surrogate markers of inflammation, endothelial dysfunction, oxidative stress and CVD in CKD patients. Moreover, inflammation and OPG levels seem to have additive effects on survival.

摘要

背景

骨保护素(OPG)是一种调节骨代谢的蛋白,其产生和表达受炎症细胞因子调节。

方法

由于临床和实验研究表明 OPG 参与动脉粥样硬化的形成,我们研究了 265 名慢性肾脏病(CKD)5 期患者的血清 OPG 与炎症、内皮功能障碍和氧化应激标志物的关系。还分析了 OPG 与心血管疾病(CVD)、颈动脉斑块(n=69)和死亡率(5 年)的关系,并评估了炎症对 OPG 与死亡率之间关联的影响。

结果

OPG 与循环中炎症、内皮功能障碍和氧化应激的替代标志物呈正相关。有临床 CVD 或颈动脉斑块的患者的 OPG 浓度高于各自的对照组。OPG 水平的升高本身与更高的心血管和全因死亡率相关,即使在调整年龄、性别、C 反应蛋白、糖尿病和基线 CVD 后也是如此。此外,炎症的存在进一步独立地加重了心血管(HR=2.8;95%置信区间[95%CI],1.3-6.4;p=0.01)和全因(HR=2.5;95%CI,1.4-4.5;p<0.01)死亡率的危险比(HR)。

结论

在 CKD 患者中,升高的 OPG 水平与炎症、内皮功能障碍、氧化应激和 CVD 的替代标志物相关。此外,炎症和 OPG 水平似乎对生存有累加效应。

相似文献

1
Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.炎症改变了骨保护素与慢性肾脏病患者死亡率的关系。
J Nephrol. 2009 Nov-Dec;22(6):774-82.
2
Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients.骨保护素水平升高可预测新透析患者的心血管事件。
Am J Nephrol. 2009;29(3):257-63. doi: 10.1159/000157629. Epub 2008 Sep 19.
3
Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality.终末期肾病患者的骨矿物质密度:与消瘦、心血管疾病及死亡率的关联
Blood Purif. 2008;26(3):284-90. doi: 10.1159/000126925. Epub 2008 Apr 18.
4
Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients.慢性透析患者中蛋白质能量消耗、炎症与心血管疾病相互作用导致的额外死亡率。
Nephrol Dial Transplant. 2008 Sep;23(9):2957-64. doi: 10.1093/ndt/gfn167. Epub 2008 Apr 9.
5
Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients.肾移植患者移植后早期血清骨保护素水平可预测长期(8年)患者生存率及心血管死亡情况。
J Am Soc Nephrol. 2006 Jun;17(6):1746-54. doi: 10.1681/ASN.2005121368. Epub 2006 May 10.
6
Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients.骨保护素水平升高与腹膜透析患者的炎症、营养不良和新发心血管事件有关。
Atherosclerosis. 2011 Dec;219(2):925-30. doi: 10.1016/j.atherosclerosis.2011.09.025. Epub 2011 Sep 21.
7
High-calcium dialysate: a factor associated with inflammation, malnutrition and mortality in non-diabetic maintenance haemodialysis patients.高钙透析液:与非糖尿病维持性血液透析患者炎症、营养不良和死亡相关的因素。
Nephrology (Carlton). 2010 Apr;15(3):313-20. doi: 10.1111/j.1440-1797.2009.01202.x.
8
Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease.骨保护素与患有心血管疾病的血液透析患者的死亡率
Clin Nephrol. 2013 Sep;80(3):161-7. doi: 10.5414/CN107803.
9
Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease.内源性促红细胞生成素与糖尿病慢性肾脏病炎症和死亡率的关系。
Clin J Am Soc Nephrol. 2011 Jul;6(7):1573-9. doi: 10.2215/CJN.00380111.
10
Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients.炎症、营养不良和心脏病作为血液透析患者死亡率的预测因素。
J Am Soc Nephrol. 2002 Jan;13 Suppl 1:S28-36.

引用本文的文献

1
Serum Osteoprotegerin Is an Independent Marker of Left Ventricular Hypertrophy, Systolic and Diastolic Dysfunction of the Left Ventricle and the Presence of Pericardial Fluid in Chronic Kidney Disease Patients.血清骨保护素是慢性肾脏病患者左心室肥厚、左心室收缩和舒张功能障碍以及心包积液的独立标志物。
Nutrients. 2022 Jul 14;14(14):2893. doi: 10.3390/nu14142893.
2
Osteoprotegerin Is a Better Predictor for Cardiovascular and All-Cause Mortality than Vascular Calcifications in a Multicenter Cohort of Patients on Peritoneal Dialysis.骨保护素是腹膜透析患者多中心队列中心血管和全因死亡率的更好预测因子,优于血管钙化。
Biomolecules. 2022 Apr 8;12(4):551. doi: 10.3390/biom12040551.
3
Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study).
韩国慢性肾脏病患者预后队列研究(KNOW-CKD研究)中未透析慢性肾脏病患者血清骨保护素水平与肾脏预后的关联
Kidney Res Clin Pract. 2022 Mar;41(2):200-208. doi: 10.23876/j.krcp.21.173. Epub 2021 Dec 29.
4
Applying Proteomics and Integrative "Omics" Strategies to Decipher the Chronic Kidney Disease-Related Atherosclerosis.应用蛋白质组学和综合“组学”策略解析慢性肾脏病相关动脉粥样硬化。
Int J Mol Sci. 2021 Jul 13;22(14):7492. doi: 10.3390/ijms22147492.
5
Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5.骨保护素是慢性肾脏病 3-5 期患者心血管死亡率的标志物。
Sci Rep. 2021 Jan 28;11(1):2473. doi: 10.1038/s41598-021-82072-z.
6
Circulating Osteoprotegerin Levels Independently Predict All-cause Mortality in Patients with Chronic Kidney Disease: a Meta-analysis.循环骨保护素水平独立预测慢性肾脏病患者的全因死亡率:一项荟萃分析。
Int J Med Sci. 2019 Sep 7;16(10):1328-1337. doi: 10.7150/ijms.34274. eCollection 2019.
7
Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease.慢性肾脏病患者单次血液透析过程中炎症和氧化应激标志物的变化。
Ren Fail. 2018 Nov;40(1):534-540. doi: 10.1080/0886022X.2018.1487857.
8
Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.慢性肾脏病中血清骨保护素水平与心血管危险因素的关系
J Clin Lab Anal. 2016 Nov;30(6):811-817. doi: 10.1002/jcla.21941. Epub 2016 Mar 17.
9
Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.在3至5期慢性肾脏病患者中,血浆骨保护素水平升高与全因死亡风险及动脉粥样硬化相关。
Braz J Med Biol Res. 2014 Nov;47(11):995-1002. doi: 10.1590/1414-431x20144007. Epub 2014 Aug 22.
10
Markers of increased cardiovascular risk in patients with chronic kidney disease.慢性肾病患者心血管风险增加的标志物。
Lipids Health Dis. 2014 Aug 21;13:135. doi: 10.1186/1476-511X-13-135.